Using the primary site as a prognostic tool for nodal mantle cell lymphoma: a SEER-based study
Publication: Journal of Comparative Effectiveness Research
Abstract
Background: Nodal mantle cell lymphoma (NMCL) has a worse survival than extra-nodal mantle cell lymphoma. Materials & methods: A cohort study was conducted to evaluate the primary site role as a mortality predictor using data from 1983 to 2011 from the Surveillance, Epidemiology, and End Results (SEER) database. Results: Most patients had NMCL in multiple regions (71.9%). There was a significantly increased incidence of NMCL cases over years with 83.2% of them occurred between 1998 and 2011. The mean survival was 52.9 months with overall survival/cancer-specific survival rate of 29.2/42.9%, respectively. Lymph nodes of intrathoracic and multiple regions had a worse overall survival while the head, face and neck, intra-abdominal, pelvic, inguinal region and leg as well as multiple regions had worse cancer-specific survival. Conclusion: NMCL primary site can serve as a prognostic factor. We encourage adding it to MCL International Prognostic Index.
Supplementary Material
File (suppl_file.docx)
- Download
- 191.89 KB
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84(5), 1361–1392 (1994).
2.
Harris NL, Jaffe ES, Diebold J et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting – Airlie House, Virginia, November 1997. J. Clin. Oncol. 17(12), 3835–3849 (1999).
3.
Samaha H, Dumontet C, Ketterer N et al. Mantle cell lymphoma: a retrospective study of 121 cases. Leukemia 12(8), 1281–1287 (1998).
4.
Mannina D, Loteta B. Ibrutinib treatment of mantle cell lymphoma relapsing at central nervous system: a case report and literature review. Case Rep. Hematol. 2017, 9583257 (2017).
5.
Cheah CY, George A, Gine E et al. Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network. Ann. Oncol. 24(8), 2119–2123 (2013).
6.
Ferrer A, Bosch F, Villamor N et al. Central nervous system involvement in mantle cell lymphoma. Ann. Oncol. 19(1), 135–141 (2008).
7.
Dreyling M, Hiddemann W. Current treatment standards and emerging strategies in mantle cell lymphoma. In: ASH Education Program Book 2009(1), 542–551 (2009).
8.
Fernandez V, Salamero O, Espinet B et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res. 70(4), 1408–1418 (2010).
9.
Bosch F, López-Guillermo A, Campo E et al. Mantle cell lymphoma. Cancer 82(3), 567–575 (1998).
10.
Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 107(1), 265–276 (2006).
11.
Zhou Y, Wang H, Fang W et al. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer 113(4), 791–798 (2008).
12.
Shiels MS, Engels EA, Linet MS et al. The epidemic of non-Hodgkin lymphoma in the United States: disentangling the effect of HIV, 1992-2009. Cancer Epidemiol. Prev. Biomark. 22(6), 1069–1078 (2013).
13.
Chandran R, Gardiner SK, Simon M, Spurgeon SE. Survival trends in mantle cell lymphoma in the United States over 16 years 1992-2007. Leuk. Lymphoma 53(8), 1488–1493 (2012).
14.
Zhou Y, Wang H, Fang W et al. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer 113(4), 791–798 (2008).
15.
Kluin-Nelemans H, Hoster E, Hermine O et al. Treatment of older patients with mantle-cell lymphoma. N. Engl. J. Med. 367(6), 520–531 (2012).
16.
Campo E, Raffeld M, Jaffe ES. Mantle-cell lymphoma. Semin. Hematol. 36(2), 115–127 (1999).
17.
Swerdlow SH, Williams ME. From centrocytic to mantle cell lymphoma: a clinicopathologic and molecular review of 3 decades. Human Pathol. 33(1), 7–20 (2002).
18.
Ambinder AJ, Shenoy PJ, Nastoupil LJ, Flowers CR. Using primary site as a predictor of survival in mantle cell lymphoma. Cancer 119(8), 1570–1577 (2013).
•• A study investigating the primary site role in extranodal mantle cell lymphoma.
19.
Rosenwald A, Wright G, Wiestner A et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 3(2), 185–197 (2003).
20.
Espinet B, Solé F, Pedro C et al. Clonal proliferation of cyclin D1-positive mantle lymphocytes in an asymptomatic patient: an early-stage event in the development or an indolent form of a mantle cell lymphoma? Human Pathol. 36(11), 1232–1237 (2005).
21.
Martin P, Chadburn A, Christos P et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J. Clin. Oncol. 27(8), 1209–1213 (2009).
22.
Nodit L, Bahler DW, Jacobs SA, Locker J, Swerdlow SH. Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes. Human Pathol. 34(10), 1030–1034 (2003).
23.
Orchard J, Garand R, Davis Z et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood 101(12), 4975–4981 (2003).
24.
Sander B. Mantle cell lymphoma: recent insights into pathogenesis, clinical variability, and new diagnostic markers. Semin. Diagn. Pathol. 28(3), 245–255 (2011).
25.
Hoster E, Dreyling M, Klapper W et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111(2), 558–565 (2008).
26.
Van De Schans SA, Janssen-Heijnen ML, Nijziel MR, Steyerberg EW, Van Spronsen DJ. Validation, revision and extension of the Mantle Cell Lymphoma International Prognostic Index in a population-based setting. Haematologica 95(9), 1503–1509 (2010).
27.
Todorovic M, Balint B, Andjelic B et al. Outcome prediction of advanced mantle cell lymphoma by international prognostic index versus different mantle cell lymphoma indexes: one institution study. Med. Oncol. 29(3), 2212–2219 (2012).
28.
Geisler CH, Kolstad A, Laurell A et al. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood 115(8), 1530–1533 (2010).
29.
Hoster E. Prognostic relevance of clinical risk factors in mantle cell lymphoma. Semin. Hematol. 48(3), 185–188 (2011).
30.
Determann O, Hoster E, Ott G et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 111(4), 2385–2387 (2008).
31.
Greiner TC, Moynihan MJ, Chan WC et al. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood 87(10), 4302–4310 (1996).
32.
Hernandez L, Fest T, Cazorla M et al. p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood 87(8), 3351–3359 (1996).
33.
Orchard J, Garand R, Davis Z et al. A subset of t (11; 14) lymphoma with mantle cell features displays mutated IgV H genes and includes patients with good prognosis, nonnodal disease. Blood 101(12), 4975–4981 (2003).
34.
Fernàndez V, Salamero O, Espinet B et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res. 70(4), 1408–1418 (2010).
35.
Ondrejka SL, Lai R, Smith SD, Hsi ED. Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis. Haematologica 96(8), 1121–1127 (2011).
36.
Furtado M, Rule S. Indolent mantle cell lymphoma. Haematologica 96(8), 1086–1088 (2011).
37.
Jurczak W, Ramanathan S, Giri P et al. Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma. Leuk. Lymphoma 59(3), 670–678 (2018).
38.
Turner JJ, Morton LM, Linet MS et al. InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. Blood 116(20), e90–e98 (2010).
39.
Morton LM, Turner JJ, Cerhan JR et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood 110(2), 695–708 (2007).
40.
Andersen N, Jensen M, De Nully Brown P, Geisler C. A Danish population-based analysis of 105 mantle cell lymphoma patients: incidences, clinical features, response, survival and prognostic factors. Eur. J. Cancer 38(3), 401–408 (2002).
• A Danish population-based study of mantle cell lymphoma investigating incidences, clinical features, response, survival and prognostic factors.
41.
Velders G, Kluin-Nelemans J, De Boer C et al. Mantle-cell lymphoma: a population-based clinical study. J. Clin. Oncol. 14(4), 1269–1274 (1996).
42.
Vose JM, Armitage J, Weisenburger D et al. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin’s lymphoma. J. Clin. Oncol. 6(12), 1838–1844 (1988).
43.
Armitage JO, Potter JF. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: increased complications with advancing age. J. Am. Geriatrics Soc. 32(4), 269–273 (1984).
44.
Cohen JB, Han X, Jemal A, Ward EM, Flowers CR. Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma. Cancer 122(15), 2356–2363 (2016).
45.
Pal SK, Hurria A. Impact of age, sex, and comorbidity on cancer therapy and disease progression. J. Clin. Oncol. 28(26), 4086–4093 (2010).
46.
Riihijärvi S, Taskinen M, Jerkeman M, Leppä S. Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy. Eur. J. Haematol. 86(2), 124–128 (2011).
47.
Kamel MG, Istanbuly S, Abd-Elhay Fa-E et al. Examined and positive lymph node counts are associated with mortality in prostate cancer: a population-based analysis. Urol. Int. (2020) (Epub ahead of print).
48.
Kamel MG, El-Qushayri AE, Thach TQ, Huy NT. Cardiovascular mortality trends in non-Hodgkin's lymphoma: a population-based cohort study. Expert Rev. Anticancer Ther. 18(1), 91–100 (2018).
49.
Elhusseiny KM, Abd-Elhay FA, Kamel MG et al. Examined and positive lymph nodes counts and lymph nodes ratio are associated with survival in major salivary gland cancer. Head Neck 41(8), 2625–2635 (2019).
50.
Abd-Elhay FA, Elhusseiny KM, Kamel MG et al. Negative lymph node count and lymph node ratio are associated with survival in male breast cancer. Clin. Breast Cancer 18(6), e1293–e1310 (2018).
51.
Guru Murthy GS, Venkitachalam R, Mehta P. Effect of radiotherapy on the survival of patients with stage I and stage II mantle cell lymphoma: analysis of the Surveillance, Epidemiology and End Results database. Clin. Lymphoma Myeloma Leuk. 14(Suppl.), S90–S95 (2014).
52.
Cronin-Fenton DP, Sharp L, Deady S, Comber H. Treatment and survival for non-Hodgkin’s lymphoma: influence of histological subtype, age, and other factors in a population-based study (1999-2001). Eur. J. Cancer 42(16), 2786–2793 (2006).
53.
Ross R, Dworsky R, Paganini-Hill A, Levine A, Mack T. Non-Hodgkin’s lymphomas in never married men in Los Angeles. Brit. J. Cancer 52(5), 785 (1985).
54.
Aizer AA, Chen M-H, Mccarthy EP et al. Marital status and survival in patients with cancer. J. Clin. Oncol. 31(31), 3869–3876 (2013).
55.
Abouyabis AN, Shenoy PJ, Lechowicz MJ, Flowers CR. Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States. Leuk. Lymphoma 49(11), 2099–2107 (2008).
56.
Koch P, Del Valle F, Berdel WE et al. Primary gastrointestinal non-Hodgkin’s lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma-results of the prospective German Multicenter Study GIT NHL 01/92. J. Clin. Oncol. 19(18), 3874–3883 (2001).
57.
Gospodarowicz MK, Bush R, Brown J, Chua T. Curability of gastrointestinal lymphoma with combined surgery and radiation. Int. J. Radiat. Oncol. Biol. Phys. 9(1), 3–9 (1983).
58.
Fleming ID, Mitchell S, Dilawari RA. The role of surgery in the management of gastric lymphoma. Cancer 49(6), 1135–1141 (1982).
59.
Paulson S, Sheehan R, Stone M, Frenkel E. Large cell lymphomas of the stomach: improved prognosis with complete resection of all intrinsic gastrointestinal disease. J. Clin. Oncol. 1(4), 263–269 (1983).
60.
Herrera A, Solal-Celigny P, Bernard J. High-risk primary lymphomas of the digestive tract: therapeutic results and study of prognostic factors. In: Non-Hodgkin's Lymphomas: New Techniques and Treatments. Sotto JJ, Vrousos C, Sotto M-F, Vincent F (Eds). Karger Publishers 206–209 (1985).
61.
Dragosics B, Bauer P, Radaszkiewicz T. Primary gastrointestinal non-Hodgkin’s lymphomas. A retrospective clinicopathologic study of 150 cases. Cancer 55(5), 1060–1073 (1985).
62.
Rosenfelt F, Rosenberg SA. Diffuse histiocytic lymphoma presenting with gastrointestinal tract lesions the stanford experience. Cancer 45(8), 2188–2193 (1980).
63.
Ampil F. Primary gastrointestinal lymphoma. Oncology 44(4), 214–218 (1987).
64.
Economopoulos T, Alexopoulos C, Stathakis N et al. Primary gastric lymphoma – the experience of a general hospital. Brit. J. Cancer 52(3), 391 (1985).
65.
Sheridan WP, Medley G, Brodie GN. Non-Hodgkin’s lymphoma of the stomach: a prospective pilot study of surgery plus chemotherapy in early and advanced disease. J. Clin. Oncol. 3(4), 495–500 (1985).
66.
Liang R, Todd D, Chan T, Ng R, Ho F. Gastrointestinal lymphoma in Chinese: a retrospective analysis. Hematol. Oncol. 5(2), 115–126 (1987).
67.
Steward WP, Harris M, Wagstaff J et al. A prospective study of the treatment of high-grade histology non-Hodgkin’s lymphoma involving the gastrointestinal tract. Eur. J. Cancer Clin. Oncol. 21(10), 1195–1200 (1985).
68.
List AF, Greer J, Cousar J et al. Non-Hodgkin’s lymphoma of the gastrointestinal tract: an analysis of clinical and pathologic features affecting outcome. J. Clin. Oncol. 6(7), 1125–1133 (1988).
69.
Shepherd FA, Evans W, Kutas G et al. Chemotherapy following surgery for stages IE and IIE non-Hodgkin’s lymphoma of the gastrointestinal tract. J. Clin. Oncol. 6(2), 253–260 (1988).
70.
Janus C, Edwards B, Sariban E, Magrath I. Surgical resection and limited chemotherapy for abdominal undifferentiated lymphomas. Cancer Treat. Rep. 68(4), 599–605 (1984).
71.
Guidot DM, Switchenko JM, Nastoupil LJ et al. Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility. Leuk. Lymphoma 1–8 (2017) (Epub ahead of print).
72.
Geisler CH, Kolstad A, Laurell A et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized Phase II multicenter study by the Nordic Lymphoma Group. Blood 112(7), 2687–2693 (2008).
73.
Kahl BS, Longo WL, Eickhoff JC et al. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. Ann. Oncol. 17(9), 1418–1423 (2006).
74.
Cortelazzo S, Ponzoni M, Ferreri AJ, Dreyling M. Mantle cell lymphoma. Crit. Rev. Oncol. Hematol. 82(1), 78–101 (2012).
75.
Armitage JO. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood 89(11), 3909–3918 (1997).
76.
Tiemann M, Schrader C, Klapper W et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Brit. J. Haematol. 131(1), 29–38 (2005).
77.
Argatoff LH, Connors JM, Klasa RJ, Horsman DE, Gascoyne RD. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood 89(6), 2067–2078 (1997).
78.
Dasappa L, Suresh Babu MC, Sirsath NT et al. Primary gastrointestinal mantle cell lymphoma: a retrospective study. J. Gastrointest. Cancer 45(4), 481–486 (2014).
79.
Salar A, Juanpere N, Bellosillo B et al. Gastrointestinal involvement in mantle cell lymphoma: a prospective clinic, endoscopic, and pathologic study. Am. J. Surg. Pathol. 30(10), 1274–1280 (2006).
80.
Morton JE, Leyland MJ, Vaughan Hudson G et al. Primary gastrointestinal non-Hodgkin’s lymphoma: a review of 175 British National Lymphoma Investigation cases. Br. J. Cancer 67(4), 776–782 (1993).
81.
Kamel MG, Abd-Elhay FA, Morsy S et al. The role of primary lymph node sites in survival and mortality prediction in DLBCL: a SEER population-based retrospective study [abstract]. Cancer Res. 78(Suppl. 13), 2215 (2018).
•• The role of primary lymph node sites in survival and mortality prediction in diffuse large B-cell lymphoma.
82.
Castillo JJ, Winer ES, Olszewski AJ. Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: an analysis of the Surveillance, Epidemiology and End Results database. Am. J. Hematol. 89(3), 310–314 (2014).
83.
Ebied A, Thanh Huan V, Makram OM et al. The role of primary lymph node sites in survival and mortality prediction in Hodgkin lymphoma: a SEER population-based retrospective study. Cancer Med. 7(4), 953–965 (2018).
• The primary site role in Hodgkin’s lymphoma patients.
84.
Swerdlow SH, Campo E, Pileri SA et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20), 2375–2390 (2016).
Information & Authors
Information
Published In
Pages: 861 - 876
PubMed: 32885984
Copyright
© 2020 Future Medicine Ltd.
History
Received: 14 May 2020
Accepted: 9 July 2020
Published online: 4 September 2020
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Using the primary site as a prognostic tool for nodal mantle cell lymphoma: a SEER-based study. (2020) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2020-0083
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Ting Zhang, Zhao-tong Wang, Zhuo Li, Shuo-xin Yin, Xun Wang, Hai-zhu Chen, The influence of marital status at diagnosis on survival of adult patients with mantle cell lymphoma, Journal of Cancer Research and Clinical Oncology, 10.1007/s00432-024-05647-z, 150, 3, (2024).
- Marcus Vinícius Ribeiro Carvalho, Carla Isabelly Rodrigues-Fernandes, Cinthia Veronica Bardález López de Cáceres, Ricardo Alves Mesquita, Manoela Domingues Martins, Elena María José Román Tager, Roman Carlos, Fábio Ramôa Pires, Liam Robinson, Willie F.P. van Heerden, Vitor Bonetti Valente, José Cândido Caldeira Xavier-Júnior, Daniel Galera Bernabé, Hélder Antônio Rebelo Pontes, Ciro Dantas Soares, Mauro Henrique Melo da Costa, Pablo Agustin Vargas, Felipe Paiva Fonseca, Mantle cell lymphoma involving the oral and maxillofacial region: a study of 20 cases, Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 10.1016/j.oooo.2022.08.018, 135, 1, (101-109), (2023).